Recent news on Letrozole

Urge activation of cancer study  -  May 24, 2007
Hendersonville Times News,The Study to Evaluate Letrozole and Raloxifene, or STELLAR, would evaluate the effectiveness of a drug that could reduce risk of breast cancer in women at

AUA 2007 - SBUR and SUO Session: Donald S. Coffey Lecture ...  -  May 20, 2007
UroToday,In her lab, it was discovered that breast cancer tumors are sensitive to both tamoxifen and the aromatase inhibitor Letrozole. Combination therapy resulted

Letter: Release funding for breast cancer research  -  May 22, 2007
Billings Gazette,...treatment and prevention, I wanted to draw your attention to the pending fate of the Study to Evaluate Letrozole and Raloxifene (STELLAR) or NSABP P-4,

Mylan Announces Tentative FDA Approval for Letrozole Tablets, USP  -  May 4, 2007
PipelineReview.com (press release),Letrozole Tablets are the generic version of Novartis Pharmaceuticals Corp.'s Femara(R) Tablets, which had US sales of approximately $326 million for the

Breast Cancer Prevention Trial in Limbo  -  May 8, 2007
Journal of American Medical Association (subscription),The $100 million phase 3 randomized, double-blind Study to Evaluate Letrozole and Raloxifene (STELLAR) trial, which would involve about 13 000 women and

Femara® Reduces Risk of Early Recurrence of Breast Cancer  -  May 11, 2007
Cancer Consultants (press release),A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New EnglandJournal of Medicine. 2005;353:2747-57.

Release funding for cancer-drug study  -  May 16, 2007
Bloomington Pantagraph,I wanted to draw your attention to the pending fate of the Study to Evaluate Letrozole and Raloxifene, or NSABP P-4, a new clinical study designed to

Breast cancer is on the rise across Middle East  -  May 8, 2007
ArabianBusiness.com,In recent trials, however, third generation aromatase inhibitors, such as Letrozole, have been shown to be more effective than Tamoxifen in advanced disease

Tentative OK for Mylan's generic Femara  -  May 3, 2007
United Press InternationalMylan's tentative approval is for its abbreviated new drug application for the 2.5 mg formulation of letrozole tablets. Novartis' Femara, which is indicated

Mylan gets tentative approval for breast cancer treatment  -  May 3, 2007
MSN MoneyCecil Township-based Mylan (NYSE:MYL) said the application was for a 2.5-milligram tablet form of letrozole. Femara had US sales of about $326 million for

Upfront Femara® Reduces Risk of Early Recurrence of Breast Cancer  -  May 15, 2007
Cancer Consultants (press release),...postmenopausal breast cancer with the aromatase inhibitor Femara® (letrozole) resulted in fewer early recurrences than treatment with tamoxifen.

Business Briefs: 5/04/07  -  May 3, 2007
Pittsburgh Post Gazette,Mylan Laboratories said it received tentative approval from the Food and Drug Administration to market Letrozole, the generic version of Novartis AG's

Japanese study shows benefits of Novartis' Diovan  -  May 1, 2007
Pharma Times (subscription),Femara (letrozole) experienced 30% fewer early breast cancer recurrences at sites away from the breast (distant metastases) compared with tamoxifen.

Secret AstraZeneca Audio Tapes: Violation of Corporate Integrity ...  -  Apr 22, 2007
OpEdNews,Two of the audio tracks show exactly how to sell AZ's Arimidex against Novartis' letrozole (brand name FEMARA), by minimizing the efficacy message of

'Grab a handful' training tapes scandal deepens  -  Apr 23, 2007
Independent,..."AstraZeneca sales, marketing and training have a co-ordinated campaign to sell against Letrozole without any comparative data. Both training examples show

Additional AstraZeneca staff disciplined  -  Apr 17, 2007
Philadelphia Inquirer,..."We should have changed our strategy with our core messages earlier in regards to selling against letrozole," Zubillaga says in the newsletter.

AstraZeneca Opens Internal Probe Into Sales Tactics  -  Apr 13, 2007
Brandweek Magazine,...“I heard early in the year at the Miami Breast Conference what letrozole was doing with their strategy. We should have changed our strategy with our core

Novartis off to a flyer in 2007 thanks to Diovan and Gleevec  -  Apr 24, 2007
Pharma Times (subscription),Other products that impressed included Femara (letrozole) for breast cancer, which rose 32% to $208 million and the epilepsy drug, Trileptal (oxcarbazepine)

Novartis licences lead cancer candidate from Antisoma  -  Apr 23, 2007
In-PharmaTechnologist.com,If approved, AS1404 will add to its current arsenal of anticancer treatments: Femara (letrozole), Glivec (imatinib), Sandostatin LAR (octreotide acetate)

Switching from Tamoxifen to Aromatase Inhibitor Improves Survival ...  -  Apr 11, 2007
Cancer Consultants (press release),Currently available aromatase inhibitors include Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole). When considering how best to use

Breast cancer patients' treatment response may help reveal cancer ...  -  Apr 6, 2007
News from Washington University in St. Louis,Three drugs — exemestane (Aromasin®), letrozole (Femara®) and anastrozole (Arimidex®) — fight breast cancer by lowering the amount of estrogen the body

Full Text  -  Mar 15, 2007
Science Magazine (subscription)The $100 million experiment aims to compare a new drug, letrozole, to older pills for preventing breast cancer in women after menopause.

Extended Adjuvant Exemestane Cuts Breast Cancer Relapse: Presented ...  -  Mar 19, 2007
DG NewsAccrual into the B-33 study stopped in October 2003 after disclosure of results from the MA-17 trial (Adjuvant Letrozole [Femara] vs Placebo in Women With

Follicular Phase Dynamics with Combined Aromatase Inhibitor and ...  -  Mar 6, 2007
Journal of Clinical Endocrinology and Metabolism,Conclusion: The addition of letrozole modifies the follicular, hormonal, and endometrial dynamics of FSH-stimulated cycles with possible positive effects on

India a hotbed for clinical trials  -  Mar 18, 2007
Times of India,In 2003, Letrozole, an anticancer drug, was tested on more than 430 young women at a dozen private clinics to find out whether it promoted ovulation.

For A Few Guineas  -  Mar 3, 2007
Outlook (subscription),Sun Pharma's Letrozole was illegally tried on 400 women across the country in 2003. Questions have also been raised about the AIDS vaccine trial.

Does industry sponsorship influence drug trial results?  -  Mar 2, 2007
DrugResearcher.com,Novartis and Pfizer also market aromatase inhibitors - called Femara (letrozole) and Aromasin (exemestane) respectively. Novartis and Pfizer were

Continuous Letrozole Better Than Continuous Tamoxifen in Early ...  -  Feb 15, 2007
Cancerpage.com,NEW YORK FEB 15, 2007 (Reuters Health) - Five years of letrozole is more effective than five years of tamoxifen as initial adjuvant therapy for

New Long-term Data Published in Journal of Clinical Oncology ...  -  Feb 21, 2007
PharmaLive.com (press release),20, 2007 – Long-term follow-up data from the independent Breast International Group (BIG) 1-98 trial support earlier findings that Femara (letrozole

New Long-term Data Published In Journal Of Clinical Oncology ...  -  Feb 20, 2007
Medical News Today (press release),Long-term follow-up data from the independent Breast International Group (BIG) 1-98 trial support earlier findings that Femara (letrozole tablets) is more

Further Evidence Supporting a Switch to Aromasin® Following Two to ...  -  Feb 14, 2007
Cancer Consultants (press release),Currently available aromatase inhibitors include Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole). When considering how best to use

Switching to newer breast cancer drugs boosts survival  -  Feb 12, 2007
Cancerfacts.com,Tamoxifen (Nolvadex®) and aromatase inhibitors such as anastrozole (Arimedex®) and letrozole (Femara®) reduce estrogen levels in the blood.

Hormone Drug Type Makes Survival Difference In Advanced Breast Cancer  -  Feb 2, 2007
Medical News Today (press release),Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the

Aromasin® Compromises Bone Health in Breast Cancer Patients  -  Jan 31, 2007
Cancer Consultants (press release),The use of the third-generation non-steroidal aromatase inhibitors Aromasin, Arimidex® (anastrozole) and Femara® (letrozole) is becoming increasingly

Poor Compliance with Adjuvant Nolvadex® Reported  -  Jan 29, 2007
Cancer Consultants (press release),There is recent evidence that Femara (letrozole) and Arimidex® (anastrozole) are more effective than Nolvadex in preventing breast cancer.

Zometa® Prevents Bone Loss in Premenopausal Breast Cancer Patients  -  Jan 17, 2007
Cancer Consultants (press release),...showed that upfront Zometa prevented cancer treatment-induced bone loss in women receiving adjuvant Femara (letrozole) (see first item in related news).

Femara® Improves Cancer-free Survival in Early Breast Cancer  -  Jan 12, 2007
Cancer Consultants (press release),Five Years of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine-responsive Early Breast Cancer: Update

Aromasin® and Faslodex® Similarly Effective and Safe As Second ...  -  Jan 2, 2007
Cancer Consultants (press release),The use of the third-generation non-steroidal aromatase inhibitors (AI) Arimidex® (anastrozole) and Femara® (letrozole) is becoming increasingly widespread

Zoledronic Acid Plus Letrozole Concurrent Treatment Prevents Bone ...  -  Dec 18, 2006
DG NewsSAN ANTONIO, TX -- December 18, 2006 -- Postmenopausal women taking adjuvant letrozole should also take concurrent zoledronic acid to prevent aromatase

Investigational Temsirolimus Fails to Improve Outcomes in Women ...  -  Dec 19, 2006
DG News..."The combination of oral temsirolimus and letrozole did not improve progression-free survival of postmenopausal women with locally advanced of metastatic

Two-Year Z-FAST Trial Shows Zoledronic Acid Prevents Bone Loss in ...  -  Dec 18, 2006
DG NewsA second group of 301 patients were assigned to initiate letrozole alone, and were given zoledronic acid only if they had a marked decreased in bone mineral

SABCS: Aromasin Ranks High for Efficacy in Unfinished Trial  -  Dec 18, 2006
MedPage Today,The study was stopped with 1598 patients enrolled -- about half of the planned 3000 -- because another trial, studying Femara (letrozole) against placebo,

Trial Comparisons Show Equal Progression Free Survival in Breast ...  -  Dec 18, 2006
DG NewsLetrozole showed a significant reduction in the risk of distant recurrence and death following a cancer event compared with tamoxifen.

Adjuvant Exemestane After Tamoxifen Improves Relapse- and Disease ...  -  Dec 18, 2006
DG NewsAccrual of the trial was stopped in October 2003, at about 50% of the planned accrual, when the NCIC MA.17 trial showed that letrozole therapy significantly

SABCS: Aromasin and Faslodex Found Equivalent in Advanced Breast ...  -  Dec 16, 2006
MedPage Today,...women with advanced breast cancer who have failed adjuvant therapy with non-steroidal aromatase inhibitors Arimidex (anastrozole) or Femara (letrozole).

Exemestane After Tamoxifen Improves Breast Cancer Survival  -  Dec 18, 2006
Cancerpage.com,In 2003, a trial of another aromatase inhibitor, letrozole (Femara Corp., East Hanover, NJ), showed strong efficacy, causing B-33 to be unblinded and

Aromasin® and Faslodex® Similarly Effective and Safe in Previously ...  -  Dec 18, 2006
Cancer Consultants (press release),Arimidex® (anastrozole) and Femara® (letrozole) are non-steroidal aromatase inhibitors. Aromasin is a steroidal aromatase inhibitor.

Estrogen-Related Genes in Malignant Breast Tumor Tissue Predict ...  -  Dec 18, 2006
DG News...more surprisingly, 7 of 38 (18%) ER-negative tumors responded favorably to treatment with the AIs (anastrozole or letrozole), with either a complete or

Infertility study shows promising results  -  Dec 7, 2006
San Antonio Express,Now, the University of Texas Health Science Center is involved in a study of two drugs, clomiphene citrate and letrozole.

Preimplantation Genetic Diagnosis for Cancer Syndromes A New ...  -  Dec 12, 2006
Journal of American Medical Association (subscription),...approaches such as use of letrozole or tamoxifen 23 ; however, these approaches have not been fully studied in patients at hereditary risk for cancer.

Letrozole Reduces Estrogen and Gonadotropin Exposure in Women with ...  Oct 27, 2006
Patients and Methods: Stages I-IIIA breast cancer patients (n = 47) received 5 mg/d letrozole and 150–300 IU FSH to cryopreserve embryos or oocytes. ... -Journal of Clinical Endocrinology and Metabolism, Serum Insulin-Like Factor 3 Levels during Puberty in Healthy Boys ...  Nov 6, 2006
10–13.9 yr. Intervention: In ISS boys, intervention included aromatase inhibitor letrozole or placebo for 24 months. Main Outcome ... -Journal of Clinical Endocrinology and Metabolism, Breast Cancer  Oct 27, 2006
The WISE trial is studying the use of a drug called, letrozole (Femara®) in women at risk for breast cancer. Letrozole is a powerful ... -WSOCtv.com, Rising breast cancer survival rates erode disease's killer image  Nov 1, 2006
..."As well as drugs like Herceptin and aromatase inhibitors such as anastrozole and letrozole, patients can also benefit from better cosmetic results which can ... -Scotsman, Breast cancer may no longer be fatal!  Nov 3, 2006
...said that women have a better chance of surviving this disease, with drugs like Herceptin and aromatase inhibitors like anastrozole and letrozole reducing the ... -Blogger News Network WELL, WELL, WELL  Oct 27, 2006
Mammography, gene testing, tamoxifen, letrozole and radical pre-emptive surgeries are being touted as the strong measures of defence necessary for those in the ... -VUE Weekly, Health Alert: Chemo prevention  Oct 23, 2006
...says Dr. Garber. Marianne is part of a double blind study looking at the drug Letrozole, which is brand named Femara. Dr. Garber ... -WIS, New four-year data confirm Femara cuts risk of breast cancer ...  Oct 13, 2006
EAST HANOVER, NJ, October 13, 2006 – New four-year data confirm that initial treatment with Femara® (letrozole tablets) following breast cancer surgery ... -PharmaLive.com (press release), Proven breast cancer treatment helps to stop the spread of cancer  Oct 10, 2006
10 /CNW Telbec/ - Today Novartis Pharmaceuticals Canada announced the Health Canada approval of Femara(*) (letrozole) as adjuvant (post-surgery) treatment for ... -Canada NewsWire (press release), Four-year Results Continue to Show Superior Outcomes with Femara® ...  Oct 16, 2006
...for Medical Oncology (ESMO) meeting, results from four years of follow-up continue to indicate that treatment with Femara® (letrozole) significantly reduces ... -Cancer Consultants (press release), Longer Follow-Up Confirms Femara® More Effective Than Nolvadex® ...  Oct 17, 2006
Researchers affiliated with the BIG-98 trial comparing Femara® (letrozole) to Nolvadex® (tamoxifen) have reported that longer follow-up confirms the ... -Cancer Consultants (press release), Vernon Harvey: Treatments extend beyond Herceptin  Oct 17, 2006
One of these medicines, Letrozole (Femara), was recently approved as initial therapy after surgery for postmenopausal women with hormone receptor-positive ... -New Zealand Herald, Novartis Gets Health Canada Approval For Femara To Treat Breast ...  Oct 10, 2006
...(RTTNews) - Novartis Pharmaceuticals Canada (NVS | charts | news | PowerRating) announced the Health Canada approval of Femara, or letrozole, as adjuvant (post ... -Trading Markets, New Breast Cancer Drug Helps Stop the Spread of Cancer  Oct 10, 2006
Novartis Pharmaceuticals Canada announced the Health Canada approval of Femara (letrozole) as post-surgery treatment for postmenopausal women with hormone ... -Toronto Daily News, Study examines whether pill can reduce estrogen, which could lead ...  Oct 17, 2006
...disease," Garber said. Marianne is part of a double blind study looking at the drug letrozole, which is brand named femara. "It's the ... -49abcnews.com, Study Identifies Women With Breast Cancer Most Likely To Benefit ...  Oct 23, 2006
A Canadian-led international clinical trial has found that post-menopausal survivors of early-stage breast cancer who took the drug letrozole after completing ... -Science Daily (press release) Aromatase Inhibitors Prolong Survival Over Tamoxifen  Sep 21, 2006
They referred specifically to four third-generation aromatase inhibitors -- Femara (letrozole), Aromasin (exemestane), Arimidex (anastrazole), and the ... -MedPage Today

Treatment Of Choice For Advanced Breast Cancer Patients: Aromatase ...  Sep 22, 2006
The authors found that third-generation aromatase inhibitors--including vorozole, letrozole, examestane, and anastrazole--increased the survival time for ... -Medical News Today

Aromatase Inhibitors Improve Survival in Women with Advanced ...  Sep 22, 2006
...recently introduced aromatase inhibitors or inactivators, such as Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole), reduced risk of ... -Cancer Consultants

In Men, Peripheral Estradiol Levels Directly Reflect the Action of ...  Sep 7, 2006
Design, Subjects, and Interventions: We suppressed aromatase activity in 10 young healthy men with letrozole 2.5 mg once daily, restored plasma estradiol ... -Journal of Clinical Endocrinology and Metabolism

Wonder Drugs  Sep 15, 2006
Duarte, Calif. Currently, three AIs have FDA approval: Arimidex (anastrazole), Aromasin (exemestane) and Femara (letrozole). Studies ... -Golf For Women Magazine

Trial of breast cancer treatments begins  Sep 3, 2006
A new family of three inhibitors had been created nearly 10 years ago, and the trial would put two of them – anastrozole and letrozole – head to head ... -Stuff.co.nz

Research and Markets: A Fourth Division for Novartis Under the ...  Sep 1, 2006
These include: Diovan (valsartan), Glivec/Gleevec (imatinib), Zelmac/Zelnorm (tegaserod), Femara (letrozole) and Zometa (zoledronate). ... -International News Service

NZ women to test new breast cancer drugs  Sep 3, 2006
...director of Waikato Hospital's Breast Care Centre Ian Campbell says the trial will test data that seems to show Femara - also known as Letrozole - is more ... -Radio New Zealand

Preimplantation Genetic Diagnosis for Cancer Syndromes A New ...  -  12 Dec 2006
Journal of American Medical Association (subscription),...approaches such as use of letrozole or tamoxifen 23 ; however, these approaches have not been fully studied in patients at hereditary risk for cancer.

Letrozole Alternative for Fertility Preservation in Breast Cancer  -  Nov 16, 2006
Cancerpage.com,NEW YORK 11-15-06 (Reuters Health) - Letrozole provides ovarian stimulation without increased estrogen and gonadotropin exposure in women with breast cancer

NICE Publishes Final Guidance For Aromatase Inhibitors, UK  -  Nov 22, 2006
Medical News Today (press release),Letrozole (Femara), Novartis: Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.

Infertility study shows promising results  -  Dec 7, 2006
San Antonio Express,Now, the University of Texas Health Science Center is involved in a study of two drugs, clomiphene citrate and letrozole.

Drug watchdog backs new breast cancer drugs  -  Nov 22, 2006
Scotsman,Anastrozole made by AstraZeneca under the brand name Arimidex, letrozole sold by Novartis as Femara and exemestane marketed as Aromasin by Pfizer are

Breast cancer hope for thousands  -  Nov 21, 2006
Guardian Unlimited,The Nice guidance recommends using the three aromatase inhibitors currently available - exemestane, anastrozole and letrozole - in different ways.

New hope for breast cancer patients  -  Nov 21, 2006
Norfolk Eastern Daily Press,There are three aromatase inhibitors currently available to patients - exemestane, anastrozole and letrozole. The Nice guidance makes recommendations for

Switching from Tamoxifen to Arimidex® Linked with Improved Survival  -  Nov 21, 2006
Cancer Consultants (press release),Currently available aromatase inhibitors include Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole). When considering how best to use

Findings from Germany, the United Kingdom and Denmark Advance ...  Jul 13, 2006
Results from two large, phase III, early adjuvant studies have indicated that the AIs letrozole and anastrozole offer greater protection against recurrence ... -Therapeutics Daily (subscription)

CGRMC News  Jul 12, 2006
...patients. The three are anastrozole, exemestane and letrozole, and they work by blocking the conversion of androgens into estrogen. ... -Casa Grande Valley Newspapers

HEALTH-INDIA: Petri Dish for Pharmaceutical MNCs  Jul 10, 2006
Already under investigation is the ‘wrong use' case of a pharmaceutical company inducing doctors to prescribe to more than 400 women ‘Letrozole', a breast ... -Inter Press Service (subscription)

Briefs: American Eagle completes building purchase  Jun 28, 2006
...enforceable patent. Novartis contends a patent on letrozole, the key ingredient in Femara, protects the drug until June 2011. • Western ... -Pittsburgh Tribune-Review

Reducing the Risk of Breast Cancer Recu  Jul 5, 2006
...surgery. The US Food and Drug Administration recently approved Femara(r) (letrozole tablets) on December 28, 2005 for this type of use. ... -Devine Media

Sales of Genentech/Roche/Chugai's Herceptin for the Treatment of ...  Jun 21, 2006
...and hormonal treatments -- will be driven by the expansion of established agents, particularly Herceptin and Novartis's Femara (letrozole), from the metastatic ... -PharmaLive.com

Femara® Approved for Initial Adjuvant Therapy in Postmenopausal ...  Jun 30, 2006
The United States Food and Drug Administration (FDA) had granted Novartis approval for their aromatase agent Femara® (letrozole) to be used as initial ... -Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional